Medical insurance bureau: list of medical prices to be built and items of dishonesty in bidding and purchasing

category:Finance
 Medical insurance bureau: list of medical prices to be built and items of dishonesty in bidding and purchasing


In order to improve the formation mechanism of market-oriented medicine price and establish the evaluation system of medicine price and bidding procurement credit, the guidance is based on the equal civil rights and obligations between the suppliers, purchasers and purchasing organizations of medicine and medical consumables, relying on the bidding and purchasing platform of medicine and medical consumables, and integrating the system of trustworthy commitment, credit rating, hierarchical disposal and credit restoration In order to protect the interests of the masses and the safety of medical insurance fund, we should establish a credit evaluation system of medical price and bidding procurement, which is equal in power and responsibility and coordinated.

The guidance proposes to establish a list of drug prices and dishonesty in bidding and procurement, including but not limited to drug commercial bribery, abuse of market dominance, manipulation of market prices, violation of contract, disruption of procurement order and other illegal, honest and fair competition behaviors. Since the date of the issuance of this opinion, pharmaceutical enterprises (including pharmaceutical and medical consumables manufacturers, distribution enterprises, the same below) will be included in the scope of medical price and bidding procurement credit evaluation if they conduct unfair competition and obtain unfair benefits through the acts listed in the catalog list in the process of pricing, bidding, performance, marketing, etc.

To deal with the dishonest and illegal behaviors of pharmaceutical enterprises at different levels

According to the requirements of reliable source, clear condition, strict procedure and strict operation, the credit rating of pharmaceutical enterprises is carried out. According to the nature, circumstances, time limit, influence scope and other factors of the dishonesty, the dishonesty of pharmaceutical enterprises in the local bidding and purchasing market is rated as four grades, i.e. general, medium, serious and especially serious, which are updated dynamically every quarter. For dishonesty such as medical commercial bribery, the facts on which credit rating is based shall be subject to the judgment of the court or the administrative penalty decision of the law enforcement department. Encourage local governments to explore credit rating methods of quantitative scoring, and constantly improve the standardization level of credit rating.

At the same time, we should deal with the breach of credit in different levels. According to the credit rating of the pharmaceutical enterprise, the centralized purchasing agency shall take such measures as written warning, warning to the purchaser of risk information, suspension of the bidding of the relevant drugs or medical consumables of the enterprise, suspension of the qualification of the enterprise to distribute the winning drugs or medical consumables, and disclosure of the dishonest information to the public, so as to consolidate the liability for breach of credit of the pharmaceutical enterprise. If the supply structure of the involved drugs or medical consumables is single and the supply and demand situation is tense, the accessibility shall be taken into account when the hierarchical treatment measures are taken to avoid the situation that the lack of clinical treatment means seriously affects the treatment of patients.

Encourage pharmaceutical enterprises to actively repair credit

It is worth mentioning that the Guiding Opinions also put forward to establish the mechanism of automatic and active credit restoration for pharmaceutical enterprises. If the Dishonesty Behavior exceeds a certain period of time, it will not be retroactively included in the scope of credit evaluation to realize automatic repair. Encourage pharmaceutical enterprises to take the initiative to repair credit, remind and inform pharmaceutical enterprises before the treatment measures take effect, and give a certain period of rectification as the case may be, accept them to take practical measures to repair credit within the rectification period, including terminating relevant dishonesty, submitting compliance rectification report, public development and issuing apology statement to eliminate adverse effects, and eliminate the virtual high space in the price of drugs or medical consumables involved , return unreasonable income, etc. At the same time, it is not allowed to intervene in the proper marketing and price of pharmaceutical enterprises by administrative means in the name of pharmaceutical price and bidding and procurement credit evaluation system, and it is not allowed to take local measures to protect and destroy fair competition. According to the state health insurance bureau, to jointly promote the construction of credit evaluation system and establish the medical price and recruitment credit evaluation system is an important measure to purify the order of the medical market, optimize the medical business environment and promote the high-quality development of the medical industry. In the future, medical institutions will be guided to give priority to pharmaceutical enterprises with better credit rating as suppliers or distribution units under the same conditions. Source: Beijing daily client editor: Wang Xiaowu_ NF

It is worth mentioning that the Guiding Opinions also put forward to establish the mechanism of automatic and active credit restoration for pharmaceutical enterprises. If the Dishonesty Behavior exceeds a certain period of time, it will not be retroactively included in the scope of credit evaluation to realize automatic repair. Encourage pharmaceutical enterprises to take the initiative to repair credit, remind and inform pharmaceutical enterprises before the treatment measures take effect, and give a certain period of rectification as the case may be, accept them to take practical measures to repair credit within the rectification period, including terminating relevant dishonesty, submitting compliance rectification report, public development and issuing apology statement to eliminate adverse effects, and eliminate the virtual high space in the price of drugs or medical consumables involved , return unreasonable income, etc.

At the same time, it is not allowed to intervene in the proper marketing and price of pharmaceutical enterprises by administrative means in the name of pharmaceutical price and bidding and procurement credit evaluation system, and it is not allowed to take local measures to protect and destroy fair competition.